

# CTO 2019 Clinical Trials Conference Agenda

## Clinical Trials Today and Tomorrow

March 27-28, 2019

Clinical trials continue to evolve as new technology and approaches to research come onto the scene. This year's conference puts the spotlight on key conversations and innovations within the clinical trials ecosystem. We will discuss how to improve clinical trials today while preparing the ground for an even stronger clinical trials environment in the future.

## Day 1 – March 27, 2019

**7:45 AM Registration, Breakfast and Networking****8:40 AM Conference Welcome**

- Susan Marlin, President and CEO, Clinical Trials Ontario
- Rafi Hofstein, Board Chair, Clinical Trials Ontario

**8:45 AM Opening Remarks**

- Giles Gherson, Deputy Minister, Red Tape and Regulatory Burden Reduction, Government of Ontario

**9:00 AM Three Decades of Transforming Care through Clinical Trials**

**Keynote:** Dr. Frances A. Shepherd, Cancer Clinical Research Unit, Princess Margaret Cancer Centre

Over the past three decades, Dr. Shepherd has designed and led more than 100 paradigm-shifting clinical trials that have changed treatment and improved outcomes for patients with lung cancer around the world. In 2018, she was awarded the prestigious Canada Gairdner Wightman Award for her global leadership in oncology. Dr. Shepherd shares her experiences with clinical trials, what has inspired her, and the critical role of clinical trials in advancing health care options for patients.

**9:30 AM Clinical Trials: What the Future Holds**

**Keynote:** Jesse Hirsh, Futurist and Digital Strategist

Living with a chronic disease, Futurist, Digital Strategist and frequent CBC contributor Jesse Hirsh has a personal stake in advancing health research. In his keynote address, Jesse will share what the future holds for our clinical trials environment and how new technology can strengthen its economic value and empower patients and the public to move the science further, faster.

**10:30 AM Morning Break and Networking****11:00 AM Health Science Our Greatest Economic Opportunity?**

Our health research and life sciences sector has significant economic value, but can we do more to unlock its potential? Are we sufficiently leveraging existing assets, investments and emerging technologies? Does our policy and regulatory environment help us or hinder us? Hear from leaders in a moderated panel discussion, following a brief presentation by Dr. Field on the current economic impact of Ontario's life sciences sector.

**Panelists:**

- Jennifer Chan, Vice President, Policy and External Affairs, Merck Canada
- Bettina Hamelin, President and CEO, Ontario Genomics
- Frank Naus, Chief Operating Officer, Allphase Clinical Research
- Michelle Noble, Executive Director, Council of Academic Hospitals of Ontario
- Nina Tangri, MPP Mississauga Streetsville

**Moderator**

- Dr. Jason Field, President and CEO, Life Sciences Ontario

**12:05 PM Lunch Break and Networking****1:15 PM Institutional Transformations to Support Clinical Trials**

Healthcare institutions are tasked with all of the demands associated with conducting high-quality research in addition to providing medical care. Hospital and research institute leaders share their experience implementing large and small-scale transformations to better support clinical research – and what's needed to promote broader improvements. Presentations will be followed by a moderated panel discussion.

**Improving Clinical Trials Operations to Support Dana-Farber Cancer Institute and Dana-Farber/Harvard Cancer Center** – Drew Memmott, Senior Vice President, Research Administration, Dana-Farber Cancer Institute

**Streamlined Study Approvals and a Structured Competency Framework: Clinical Research Innovations at The Hospital for Sick Children**

Lisa Goos, Director of Clinical Research Services, The Hospital for Sick Children

**Clinical Trials and Community Hospitals: Opportunities and Barriers**  
Speaker(s) to be announced

**Moderator**

Andy Smith, President and CEO, Sunnybrook Health Sciences Centre

**2:25 PM Regulatory Changes and Clinical Trials in Canada: Plans and Possibilities**

Learn about Health Canada's recent regulatory changes and plans for the future, followed by updates from the Life-Saving Therapies Network and how regulatory measures governing clinical trials conduct could support timely patient access to life-saving therapies.

**Health Canada's Current Activities and Direction for Clinical Trials Involving Drugs**

Carole Légaré, BSc, MD, CCFP, Cert PE & PV, Director, Office of Clinical Trials, Health Products and Food Branch, Health Canada

**Regulatory Reform and Patient-Led Clinical Trials**

John-Peter Bradford, Life Saving Therapies Network

**3:15 PM Afternoon Break and Networking****3:40 PM Keeping the Science Ahead of Me: Perspectives on Clinical Trials**

Health research isn't a luxury. For many, it's a necessity. A patient, an advocate and a scientist share their unique perspectives on the critical need for ongoing clinical research and how we, as a clinical trials community, can best support the development of, and access to, better therapies for patients. Panel discussion moderated by John Adams.

**More Lifeboats Please**

John Adams, Board Chair, Best Medicines Coalition (presenter/moderator)

**Lessons from Entering the Clinical Trials Era in Huntington's disease**

Ray Truant, Professor, Biochemistry and Biomedical Sciences, McMaster University

**Presentation Title to be Announced**

Patrick Cupido, Past Chair, CATIE (Canadian Aids Treatment Information Exchange)

**Clinical Trials: A Lifeline for Patients with Rare Diseases**

Durhane Wong-Rieger, President and CEO, Canadian Organization for Rare Disease

**4:50 PM Day One Closing Remarks****5:00 PM Networking Reception****Day 2 – March 28, 2019****8:00 AM Breakfast and Networking****8:45 AM Day Two Welcome Remarks**

Susan Marlin, President and CEO, Clinical Trials Ontario

**8:50 AM Think Big: Applying Emerging Technologies to Improve Public Health Outcomes**

**Keynote:** Michael Jackson, Leader, Public Health and US Elections, Amazon Web Services

Data and digital technology hold great promise for our health care system. But Michael Jackson, Leader of Public Health at Amazon Web Services, encourages us to think even bigger. In his keynote address, Michael will share how new collaborations between corporations, innovators and governments are leveraging emerging technologies to target the social determinants of health and drive deep, lasting improvements for public health outcomes.

**9:30 AM The Data Revolution: How AI, Tech and Real-World Evidence are Transforming Clinical Trials**

How are emerging technologies and data capabilities changing traditional clinical trials? What does the future hold for understanding, preventing and treating disease? Digital health pioneers and AI experts share perspectives on the clinical trials of tomorrow, and how we can start moving forward today. Presentations will be followed by a panel discussion moderated by Michael Jackson.

**How Microsoft Azure and AI Tools Can Improve Outcomes**

Peter Jones, Industry Lead, Healthcare, Microsoft Canada

**Examples of Innovation in Real World Evidence**

Brad Millson, Senior Principal, Health Access and Outcomes, IQVIA Canada

**Facts and Fictions: How AI Can Augment and Disrupt Clinical Trial Methodologies Today and Tomorrow**

Eric Gildenhuis, Vice-President of Business Development, Deep 6 AI

**Moderator**

Michael Jackson, Leader, Public Health and US Elections, Amazon Web Services

**10:50 AM Morning Break and Networking**

**11:15 AM Ethics Issues with Pragmatic Clinical Trials**

Cluster randomization is an increasingly important design in the pragmatic clinical trials agenda. However, cluster randomized trials raise important methodological and ethical considerations which challenge researchers and research ethics committees. In this session, a bioethicist, statistician, and pragmatic clinical trial expert will review these challenges in the context of real-world pragmatic cluster randomized trials in orthopaedic trauma.

**Methodological Considerations in Pragmatic Cluster Randomized Trials**

Monica Taljaard, Senior Scientist, Clinical Epidemiology Program, Ottawa Hospital Research Institute

**Ethical Considerations in Pragmatic Cluster Randomized Trials**

Charles Weijer, Professor, Canada Research Chair in Bioethics at the Rotman Institute of Philosophy at Western University

**PREP-IT: A Program of Randomized trials to Evaluate Pre-operative antiseptic skin solutions In orthopaedic Trauma**

Dr. Shelia Sprague, Assistant Professor Department of Surgery, McMaster University

**12:15 PM Lunch Break and Networking****1:30 PM Borrowing from Ethics: The Evolution of Privacy in Research**

**Keynote:** Kris Klein, Partner, nNovation LLP

Privacy is not a barrier. Kris Klein, Partner at nNovation LLP will share how adhering to fundamental privacy principles will enable ethical research, sharing case studies that involve exploring ethical research using personal health information. Privacy itself is learning from the REB world and there are many parallels to be drawn. The future of privacy will borrow heavily from the REB world so that privacy continues to be an enabler – not a barrier.

**2:15 PM Mind the App: Ethical and Legal Issues in mHealth Applications for Research and the Clinic**

Ma'n H. Zawati (LL.B., LL.M., Ph.D. (DCL)), Executive Director, Centre of Genomics and Policy, Department of Human Genetics, McGill University

Wearable and mobile devices that record and organize personal health information are increasingly popular. While this kind of information promises to empower consumers, it also raises legal and ethical questions about data management, privacy, and how we make decisions about our health. Ma'n Zawati, Executive Director of the Centre of Genomics and Policy at McGill University will use the Canadian legal landscape to outline the issues and describe how new technology may be harnessed in ways that empower patients and society.

**2:45 PM Afternoon Break and Networking****3:00 PM Collaborating for Engagement, Efficiency and Impact**

Collaboration is key enabler of more efficient trials, better methods for patient and public engagement and ultimately, greater impact. In this session, researchers and community partners share their approach to collaboration and its central role in advancing clinical trials and research.

**Family engagement in research: Authentically and meaningfully partnering with families in the pediatric disability research context**

- Sharon Gabison, PhD, Holland Bloorview Family Leader and Co-Chair, Research Family Engagement Committee
- Beth Dangerfield, BA, BEd, OCT, Family Partnership Specialist, Holland Bloorview Kids Rehabilitation Hospital
- Nadia Tanel, MEd, Director, Research Operation, Bloorview Research Institute

**Promoting Child Health Research through a Collaborative Approach to a Streamlined Ethics Review**

Dr. Shoo K. Lee, MBBS, PhD, FRCPC, DHC, Scientific Director, Canadian Institutes of Health Research Institute of Human Development, Child and Youth Health

**The Rethinking Clinical Trials (REaCT) Program: Using Collaboration to Change the Face of Oncology Trials in Canada**

Dr. Mark Clemens, Clinical Investigator, Ottawa Hospital Research Institute

**4:15 PM Day Two Closing Remarks**